Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06023589

PHASE3

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

Official title: A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)

Key Details

Gender

All

Age Range

5 Years - 11 Years

Study Type

INTERVENTIONAL

Enrollment

231

Start Date

2023-08-24

Completion Date

2030-08-23

Last Updated

2026-04-01

Healthy Volunteers

Conditions

Asthma

Interventions

BIOLOGICAL

Tezepelumab

Participants will be receiving subcutaneous injection of tezepelumab

OTHER

Placebo

Participants will be receiving subcutaneous injection of matching placebo

Inclusion Criteria: 1. Written informed consent from (ICF) at least one parent/caregiver (as per local guidelines) and accompanying informed assent from the participant (where the participant is able to provide assent) prior to admission to the study. 2. Participants must be 5 to \< 12 years of age, at the time of signing the assent form (as applicable per local guidelines) and their caregivers signing the ICF and at Visit 3. 3. Documented physician diagnosis of severe asthma confirmed and evaluated for at least 6 months prior to Visit 1. 4. Documented physician-prescribed treatment with a total daily dose of either medium or high dose, for at least 3 months with stable dose ≥ 1 month prior to Visit 1. 5. Documented treatment with at least one additional maintenance asthma controller medication is required according to local guidelines and standard of care; (long-acting beta agonist, leukotriene receptor antagonist, long-acting muscarinic antagonist) for at least 3 months with stable dose ≥ 1 month prior to Visit 1. 6. Supportive evidence of asthma as documented by one of the following: 1. Post-BD (albuterol/salbutamol) responsiveness of FEV1 ≥ 10% during Screening (15 to 30 min after administration of 4 puffs of albuterol/salbutamol with a maximum of 12 puffs of reliever medication only if tolerated by the participant) at either Visit 1 or Visit 2. If (a) is not achieved at Visit 1 or Visit 2, historical documentation by any of the below prior to Visit 1: 2. Post-BD responsiveness of FEV1 ≥ 10%. 3. Positive methacholine challenge defined as provocative concentration (PC20) of ≤ 16 mg/mL. 4. PEF average daily diurnal variability \> 13% over a 2-week period. 5. Variability of FEV1 ≥ 12% between any two clinical visits. 6. Positive exercise challenge test (defined as a fall in FEV1 of \> 12%). 7. FeNO ≥ 20 ppb despite confirmed ICS maintenance therapy. 7. History of at least 2 severe asthma exacerbation events OR 1 severe asthma exacerbation event resulting in hospitalisation within 12 months prior to Visit 1. 8. Pre-BD FEV1 \>50% and ≤ 95%PN OR FEV1/forced vital capacity (FVC) ratio ≤ 0.85 at either Visit 1 or Visit 2. 9. Evidence of uncontrolled asthma, with at least 1 of the below criteria: 1. ACQ-IA score ≥ 1.5 at least once during Screening/Run-in, including Visit 3 (prior to Randomisation) for participants ≥ 6 years old at Screening. 2. Use of reliever medication, other than as a preventive for exercise induced bronchospasm, on 3 or more days per week for at least 1 week during the Screening/Run-in period. 3. Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening/Run-in period. 4. Asthma symptoms 3 or more days per week in at least 1 week during the Screening/Run-in period. 10. Body weight ≥ 16 kg at Visit 1 (Screening) and Visit 3 (Randomisation). Exclusion Criteria: 1. History of vocal cord dysfunction, cystic fibrosis, primary ciliary dyskinesia, or chronic rhinosinusitis with nasal polyposis. 2. History of any clinically significant disease or disorder other than asthma which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. 3. History of a clinically significant deterioration in asthma or asthma exacerbation including those requiring use of systemic corticosteroids or increase in the maintenance dose of oral corticosteroids within 30 days prior to Visit 1. 4. Change in ICS dose within 1 month prior to Visit 1. 5. History of a life-threatening asthma exacerbation resulting in a hypoxic seizure or requiring intubation.

Locations (143)

Research Site

Montgomery, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

Little Rock, Arkansas, United States

Research Site

La Jolla, California, United States

Research Site

Long Beach, California, United States

Research Site

Orange, California, United States

Research Site

San Diego, California, United States

Research Site

Atlanta, Georgia, United States

Research Site

Savannah, Georgia, United States

Research Site

Baltimore, Maryland, United States

Research Site

Boston, Massachusetts, United States

Research Site

Boston, Massachusetts, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Detroit, Michigan, United States

Research Site

Northfield, New Jersey, United States

Research Site

Hawthorne, New York, United States

Research Site

Schenectady, New York, United States

Research Site

Staten Island, New York, United States

Research Site

Chapel Hill, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cleveland, Ohio, United States

Research Site

Toledo, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Columbia, South Carolina, United States

Research Site

Coppell, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

Frisco, Texas, United States

Research Site

Houston, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Temple, Texas, United States

Research Site

Buenos Aires, Argentina

Research Site

Buenos Aires, Argentina

Research Site

Buenos Aires, Argentina

Research Site

CABA, Argentina

Research Site

Florida, Argentina

Research Site

Lanús, Argentina

Research Site

Lobos, Argentina

Research Site

Mendoza, Argentina

Research Site

Quilmes, Argentina

Research Site

Rosario, Argentina

Research Site

Blumenau, Brazil

Research Site

Curitiba, Brazil

Research Site

Salvador, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Sorocaba, Brazil

Research Site

Edmonton, Alberta, Canada

Research Site

Burlington, Ontario, Canada

Research Site

Hamilton, Ontario, Canada

Research Site

Windsor, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Lanzhou, China

Research Site

Nanjing, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shenzhen, China

Research Site

Wuxi, China

Research Site

Bogotá, Colombia

Research Site

Bogotá, Colombia

Research Site

Medellín, Colombia

Research Site

Brest, France

Research Site

Bron, France

Research Site

Créteil, France

Research Site

Marseille, France

Research Site

Paris, France

Research Site

Paris, France

Research Site

Paris, France

Research Site

Rouen, France

Research Site

Vandœuvre-lès-Nancy, France

Research Site

Debrecen, Hungary

Research Site

Szeged, Hungary

Research Site

Szigetvár, Hungary

Research Site

Genova, Italy

Research Site

Pavia, Italy

Research Site

Roma, Italy

Research Site

Fukuoka, Japan

Research Site

Fukuoka, Japan

Research Site

Fukuyama, Japan

Research Site

Funabashi-shi, Japan

Research Site

Nara, Japan

Research Site

Odawara, Japan

Research Site

Ōtsu, Japan

Research Site

Saga, Japan

Research Site

Shimotsuga-gun, Japan

Research Site

Yokohama, Japan

Research Site

Chihuahua City, Mexico

Research Site

Guadalajara, Mexico

Research Site

Mexico City, Mexico

Research Site

Veracruz, Mexico

Research Site

Amsterdam, Netherlands

Research Site

Rotterdam, Netherlands

Research Site

Iloilo City, Philippines

Research Site

Las Piñas, Philippines

Research Site

Quezon, Philippines

Research Site

Santa Rosa, Philippines

Research Site

Lodz, Poland

Research Site

Tarnów, Poland

Research Site

Bucharest, Romania

Research Site

Bucharest, Romania

Research Site

Bellville, South Africa

Research Site

Cape Town, South Africa

Research Site

Durban, South Africa

Research Site

Durban, South Africa

Research Site

Middelburg, South Africa

Research Site

Thabazimbi, South Africa

Research Site

Vereeniging, South Africa

Research Site

Welkom, South Africa

Research Site

Seongnam-si, South Korea

Research Site

Seongnam-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Badalona, Spain

Research Site

Barcelona, Spain

Research Site

Esplugues de Llobregat (Barc), Spain

Research Site

Madrid, Spain

Research Site

Sabadell, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Villarreal, Spain

Research Site

Bangkok, Thailand

Research Site

Bangkoknoi, Thailand

Research Site

Chiang Mai, Thailand

Research Site

Muang, Thailand

Research Site

Bursa, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Yenimahalle, Turkey (Türkiye)

Research Site

Chernivtsi, Ukraine

Research Site

Ivano-Frankivsk, Ukraine

Research Site

Kyiv, Ukraine

Research Site

Kyiv, Ukraine

Research Site

Birmingham, United Kingdom

Research Site

Bradford, United Kingdom

Research Site

Bristol, United Kingdom

Research Site

Glasgow, United Kingdom

Research Site

Leicester, United Kingdom

Research Site

London, United Kingdom

Research Site

Nottingham, United Kingdom

Research Site

Stoke-on-Trent, United Kingdom

Clinical Research Directory

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (143)